President Expected to Address Drug Prices in State of the Union Message In his State of the Union address tonight, President Trump is expected to announce an initiative to make insulin more affordable and to challenge Congress to pass legislation …
Category: Federal
CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear The Centers for Medicare & Medicaid Services (CMS) this morning invited state Medicaid directors to pilot test giving up open-ended federal Medicaid funding for able-bodied adults in exchange for a …
Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law” Hospital group 340B Health yesterday swung back hard against a congressional watchdog agency’s recommendations for stricter federal policing of 340B duplicate discounts, calling them “misguided, unworkable, and contrary to …
BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts …
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of …
MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs The Medicare Payment Advisory Commission (MedPAC) will hear from its staff on Jan. 17 about whether the 340B program gives participating hospitals an incentive to use …
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts on …
BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus The Health Resources and Services Administration (HRSA) announced this morning that it has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process. “The 340B Prime Vendor …
Greetings Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news. BREAKING: Drugmaker Xspire Owes 340B Refunds Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds for …